Variables
|
Number of SMD included
|
Subgroups
|
Pooled OR (random effect)
|
95% CI
|
I2 (%)
|
overall I2(%)
|
---|
CRP
|
Geographic area
|
6
|
Asia
|
−1.20
|
−2.02, − 0.38
|
90.8
|
93.7
|
5
|
European
|
−2.52
|
−4.26, −0.78
|
94.8
|
1
|
USA
|
−0.46
|
− 0.98, 0.07
|
–
|
1
|
Oceania
|
0.05
|
−0.41, 0.51
|
–
|
Dosage of ALA (mg/day)
|
4
|
< 600
|
−1.29
|
−2.16, −0.42
|
81.4
|
9
|
≥600
|
−1.64
|
−2.61, −0.66
|
95.4
|
Type of intervention
|
9
|
ALA
|
−1.63
|
−2.67, −0.58
|
95.3
|
4
|
ALA plus other nutrients
|
−1.30
|
−2.10, −0.50
|
85.0
|
Duration of study (week)
|
10
|
≥8
|
−1.50
|
−2.35, −0.65
|
94.4
|
3
|
< 8
|
−1.63
|
−2.93, −0.32
|
88.6
|
Type of diseases
|
3
|
Diabetic
|
−1.63
|
−2.93, −0.32
|
88.6
|
10
|
Other
|
−1.50
|
−2.35, −0.65
|
94.4
|
IL-6
|
Geographic area
|
4
|
Asia
|
−2.18
|
−3.34, −1.02
|
88.7
|
90.6
|
6
|
European
|
−1.75
|
−2.71, −0.78
|
87.4
|
3
|
USA
|
−4.10
|
−7.68, −0.52
|
96.3
|
1
|
Oceania
|
−0.26
|
−0.72, 0.20
|
–
|
1
|
Africa
|
−0.57
|
−1.17, 0.03
|
–
|
Dosage of ALA (mg/day)
|
5
|
< 600
|
−3.59
|
−5.50, −1.68
|
94.8
|
10
|
≥600
|
−1.22
|
− 1.70, −0.74
|
78.4
|
Type of intervention
|
8
|
ALA
|
−2.00
|
−2.88, −1.11
|
90.9
|
7
|
ALA plus other nutrients
|
−1.98
|
−3.01, −0.95
|
91.7
|
Duration of study (week)
|
8
|
≥8
|
−1.07
|
− 1.62, −0.52
|
85.1
|
7
|
< 8
|
−3.30
|
−4.61, −1.99
|
89.9
|
Type of diseases
|
2
|
Diabetic
|
−3.40
|
−5.13, −1.66
|
75.1
|
13
|
Other
|
−1.72
|
−2.35, − 1.09
|
89.5
|
TNF-α
|
Geographic area
|
3
|
Asia
|
−2.44
|
−4.67, −0.21
|
95.9
|
94.3
|
5
|
European
|
−2.63
|
−3.87, −1.39
|
87.2
|
1
|
Oceania
|
−0.34
|
− 0.80, 0.12
|
–
|
1
|
Africa
|
−6.35
|
−8.16, −4.54
|
–
|
Dosage of ALA (mg/day)
|
1
|
< 600
|
−2.14
|
−2.77, −1.51
|
–
|
9
|
≥600
|
−2.71
|
−3.94, − 1.48
|
94.7
|
Type of intervention
|
6
|
ALA
|
−2.56
|
−4.08, −1.03
|
95.8
|
4
|
ALA plus other nutrients
|
−2.73
|
−4.26, −1.20
|
89.3
|
Duration of study (week)
|
5
|
≥8
|
−2.78
|
−4.57, −0.99
|
96.8
|
5
|
< 8
|
−2.40
|
−3.46, −1.33
|
80.2
|
Type of diseases
|
3
|
Diabetic
|
−4.68
|
−7.82, −1.55
|
92.8
|
7
|
Other
|
−1.89
|
−3.04, −0.73
|
94.0
|
- ESRD end-stage renal disease, IL-6 interlokin-6, CRP C-reactive protein, TNF-α tumor necrosis factor alpha